IMC’s members continue to have significant concerns regarding changes to the PMPRB and future Guidelines that will implement the revised schedule of international reference countries.
Our resource hub to discover reports, policy papers and other forms of informative content
IMC supports the creation of a Pan Canadian Genomics Strategy (PCGS) to help Canada advance its international leadership and increase capacity in genomics through commercialization and adoption.
Use this tool to search for brand name drugs to view their current negotiation status.
Optimizing Patient Access to Precision Therapies: Preparing for the Emerging Era of Advanced Testing
This policy note characterizes Canada’s current testing infrastructure and its limitations, which include that it hinders current and future patient access to the best available treatments.
Our Code of Ethical Practices guides the activities of all our members’ employees as they interact with stakeholders to commercialize prescription medicines (excluding medical devices and over-the-counter products). Adherence to the Code is a condition of membership.
Canadians relying on public insurance plans face significant delays accessing new medicines. This graph breaks down the sequential approval and listing process, and demonstrates how long it takes Canadians to access innovative medicines.
Statistic’s Canada outlines the economic impact of the Canadian research and development pharmaceutical sector.
Clinical trials provide Canadian oncology patients with earlier access to new, innovative cancer treatments. But changes pending to the PMPRB will make the Canadian pharmaceutical market less attractive for investment.